CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.

Thomas Melchardt (First author), Clemens Hufnagl (First author), Teresa Magnes (Co-author), Lukas Weiss (Co-author), Georg Hutarew (Co-author), Daniel Neureiter (Co-author), Alexander Schlattau (Co-author), Gerhard Moser (Co-author), Alexander Gaggl (Co-author), Wolfgang Tränkenschuh (Co-author), Richard Greil (Co-author), Alexander Egle* (Last author)

*Corresponding author for this work

Research output: Contribution to journalOriginal Articlepeer-review

11 Citations (Web of Science)
Original languageEnglish
Pages (from-to)725
JournalBMC CANCER
Volume15
DOIs
Publication statusPublished - 2015

Keywords

  • LOCALLY ADVANCED HEAD
  • SQUAMOUS-CELL CARCINOMA
  • CONCURRENT RADIOTHERAPY
  • DOCETAXEL
  • CISPLATIN
  • FLUOROURACIL
  • CHEMORADIOTHERAPY
  • 5-FLUOROURACIL
  • CETUXIMAB
  • TRIAL

Cite this